Physician profile
Robert Gin
NPI 1811966575
$9,099.24
in general payments reported to CMS, 2019-2025
57 companies · $892 in 2025
The $892 reported for 2025 was more than what 82% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,387 · 2020: $3,167 · 2022: $739 · 2023: $1,580 · 2024: $1,334 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,806.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,536.19 | 2019-2025 | Lynparza, Enhertu |
| Merck Sharp & Dohme LLC | $591.50 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $406.28 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $370.83 | 2023-2025 | Orgovyx |
| Incyte Corporation | $334.49 | 2019-2025 | Jakafi, Monjuvi |
| Regeneron Healthcare Solutions, INC. | $329.75 | 2019-2024 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $326.09 | 2019-2025 | |
| Amgen INC. | $321.40 | 2019-2023 | Kyprolis, Blincyto |
| Janssen Biotech, INC. | $319.11 | 2019-2024 | Rybrevant, Darzalex, Talvey |
| Pfizer INC. | $300.62 | 2019-2024 | |
| Abbvie INC. | $145.22 | 2022-2025 | |
| Genentech USA, INC. | $138.82 | 2019-2025 | Perjeta, Phesgo, Alecensa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.89 | 2019-2025 | Gilotrif |
| Daiichi Sankyo INC. | $112.93 | 2020-2025 | Enhertu, Datroway |
| Sobi, INC | $99.68 | 2022-2025 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.